BACKGROUND: Advanced glycation end products (AGEs) are implicated in the complications of diabetes. Advanced glycation end products also accumulate in the skin and are sensitive biomarkers for the risk of developing diabetes and related complications. Some AGEs fluoresce and can be measured noninvasively by optical spectroscopy. METHODS: Noninvasive screening for diabetes has been evaluated in an 18-site study involving a cohort of 2793 subjects meeting American Diabetes Association-based screening criteria. Subjects were measured with a specialized skin fluorimeter and also received traditional blood glucose and glycated hemoglobin tests. RESULTS: Retrospective results indicated that the noninvasive technology measuring dermal fluorescence is more sensitive at detecting abnormal glucose tolerance than either fasting plasma glucose or glycated hemoglobin A1C. CONCLUSIONS: These results suggest that noninvasive measurement of dermal fluorescence may be an effective tool to identify individuals at risk for diabetes and its complications. The noninvasive technology yields immediate results, and since measuring dermal fluorescence requires no blood draws or patient fasting, the instrument may be well suited for opportunistic screening. Copyright 2009 Diabetes Technology Society.
BACKGROUND: Advanced glycation end products (AGEs) are implicated in the complications of diabetes. Advanced glycation end products also accumulate in the skin and are sensitive biomarkers for the risk of developing diabetes and related complications. Some AGEs fluoresce and can be measured noninvasively by optical spectroscopy. METHODS: Noninvasive screening for diabetes has been evaluated in an 18-site study involving a cohort of 2793 subjects meeting American Diabetes Association-based screening criteria. Subjects were measured with a specialized skin fluorimeter and also received traditional blood glucose and glycated hemoglobin tests. RESULTS: Retrospective results indicated that the noninvasive technology measuring dermal fluorescence is more sensitive at detecting abnormal glucose tolerance than either fasting plasma glucose or glycated hemoglobin A1C. CONCLUSIONS: These results suggest that noninvasive measurement of dermal fluorescence may be an effective tool to identify individuals at risk for diabetes and its complications. The noninvasive technology yields immediate results, and since measuring dermal fluorescence requires no blood draws or patient fasting, the instrument may be well suited for opportunistic screening. Copyright 2009 Diabetes Technology Society.
Authors: Robbert Meerwaldt; Helen L Lutgers; Thera P Links; Reindert Graaff; John W Baynes; Rijk O B Gans; Andries J Smit Journal: Diabetes Care Date: 2007-01 Impact factor: 19.112
Authors: Saul Genuth; Wanjie Sun; Patricia Cleary; David R Sell; William Dahms; John Malone; William Sivitz; Vincent M Monnier Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: V M Monnier; O Bautista; D Kenny; D R Sell; J Fogarty; W Dahms; P A Cleary; J Lachin; S Genuth Journal: Diabetes Date: 1999-04 Impact factor: 9.461
Authors: R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit Journal: Diabetologia Date: 2004-07-09 Impact factor: 10.122
Authors: Shuang Feng Chen; Zuo Li Xia; Ji Ju Han; Yi Ting Wang; Ji Yue Wang; Shao Dong Pan; Ya Ping Wu; Bin Zhang; Guang Yao Li; Jing Wei Du; Hen Qiang Gao; Philip G de Groot; Bas de Laat; Martine J Hollestelle Journal: Age (Dordr) Date: 2011-11-27
Authors: Baqiyyah N Conway; Vanita R Aroda; John D Maynard; Nathaniel Matter; Stephen Fernandez; Robert E Ratner; Trevor J Orchard Journal: Diabetes Care Date: 2011-02-09 Impact factor: 19.112
Authors: Baqiyyah N Conway; Vanita R Aroda; John D Maynard; Nathaniel Matter; Stephen Fernandez; Robert E Ratner; Trevor J Orchard Journal: Diabetes Care Date: 2012-07-30 Impact factor: 19.112